Arsenic Trioxide: Its Use in the Treatment of Acute Promyelocytic Leukemia

By Sanz Miguel A.  

American Journal of Cancer, Vol. 5, Iss. 3, 2006-01 ,pp. : 183-191

Adis International

Access to resources Recommend Favorite

Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?

By Firkin Frank  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 977-978

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

By Fujisawa Shinya   Ohno Ryuzo   Shigeno Kazuyuki   Sahara Naohi   Nakamura Satoki   Naito Kensuke   Kobayashi Miki   Shinjo Kaori   Takeshita Akihiro   Suzuki Yoshinari   Hashimoto Hisakuni   Kinoshita Kenji   Shimoya Masahito   Kaise Toshikazu   Ohnishi Kazunori  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 485-493

Springer Publishing Company

Access to resources Recommend Favorite

Delphinidin induces cytotoxicity and potentiates cytocidal effect in combination with arsenite in an acute promyelocytic leukemia NB4 cell line

By                

Oncology Reports, Vol. 34, Iss. 1, 2015-01 ,pp. : 431-438

Spandidos Publications

Access to resources Recommend Favorite

Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A

By                

Oncology Reports, Vol. 28, Iss. 5, 2012-01 ,pp. : 1875-1882

Spandidos Publications

Access to resources Recommend Favorite